1. Home
  2. RGEN vs SRPT Comparison

RGEN vs SRPT Comparison

Compare RGEN & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • SRPT
  • Stock Information
  • Founded
  • RGEN 1981
  • SRPT 1980
  • Country
  • RGEN United States
  • SRPT United States
  • Employees
  • RGEN N/A
  • SRPT N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RGEN Health Care
  • SRPT Health Care
  • Exchange
  • RGEN Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • RGEN 7.1B
  • SRPT 9.8B
  • IPO Year
  • RGEN N/A
  • SRPT 1997
  • Fundamental
  • Price
  • RGEN $128.50
  • SRPT $61.91
  • Analyst Decision
  • RGEN Buy
  • SRPT Buy
  • Analyst Count
  • RGEN 12
  • SRPT 21
  • Target Price
  • RGEN $177.78
  • SRPT $160.52
  • AVG Volume (30 Days)
  • RGEN 756.1K
  • SRPT 2.4M
  • Earning Date
  • RGEN 04-30-2025
  • SRPT 04-30-2025
  • Dividend Yield
  • RGEN N/A
  • SRPT N/A
  • EPS Growth
  • RGEN N/A
  • SRPT N/A
  • EPS
  • RGEN N/A
  • SRPT 2.34
  • Revenue
  • RGEN $634,439,000.00
  • SRPT $1,901,979,000.00
  • Revenue This Year
  • RGEN $12.24
  • SRPT $69.30
  • Revenue Next Year
  • RGEN $15.24
  • SRPT $22.64
  • P/E Ratio
  • RGEN N/A
  • SRPT $26.48
  • Revenue Growth
  • RGEN 0.33
  • SRPT 52.97
  • 52 Week Low
  • RGEN $113.50
  • SRPT $61.53
  • 52 Week High
  • RGEN $182.52
  • SRPT $173.25
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 34.73
  • SRPT 22.79
  • Support Level
  • RGEN $135.71
  • SRPT $70.91
  • Resistance Level
  • RGEN $147.00
  • SRPT $76.67
  • Average True Range (ATR)
  • RGEN 6.09
  • SRPT 4.29
  • MACD
  • RGEN -1.57
  • SRPT -1.71
  • Stochastic Oscillator
  • RGEN 12.43
  • SRPT 0.92

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: